Clinical Relevance of Cyclic GMP Modulators: A Translational Success Story of Network Pharmacology

Therapies that modulate cyclic guanosine-30-50-monophosphate (cGMP) have emerged as one of the most successful areas in recent drug discovery and clinical pharmacology. Historically, their focus has been on cardiovascular disease phenotypes; however, cGMP's relevance is likely to go beyond this rather limited organ-based set of indications. Moreover, the multitude of targets and their apparent interchangeability is a proof-of-concept of network pharmacology.